Background. Advanced fibrosis or cirrhosis is still regarded as a contraindication for kidney transplantation alone by most centers. The value of aminotransferase to platelet ratio index (APRI) and other non-invasive markers has been less studied in hepatitis C virus (HCV)-positive patients with concurrent end-stage renal disease to predict hepatic fibrosis. Can these be used to effectively decrease the number of biopsies done in these patients being evaluated for transplantation? Methods. Our study population included 255 patients with liver biopsy data. All patient information was collected and reviewed from medical records. The diagnostic accuracy of the predictive models was analyzed by calculating sensitivity, specificity, positive predictive value and negative predictive value. Results. The variables associated with F3-F4 were aspartate aminotransferase (P = 0.007), bilirubin (P ≤ 0.001), platelet count (P = 0.01) and APRI (P ≤ 0.001). The use of any one laboratory abnormality to predict liver biopsy scores did not show high positive predictive values (22.6-72.7%). Having abnormal liver findings or cirrhosis on imaging was associated with high specificities (92.0-97.8%) but low sensitivities (31.4-42.9%). Using APRI levels of ≥0.40 and ≤0.95 as an indication for liver biopsy, 50% of patients with F3-F4 would have correctly avoided having a biopsy. However, 33% of patients with F3-F4 would have been mislabeled and not be indicated for biopsy. Conclusions. Our data suggest that there may not currently be a simple and sufficiently accurate non-invasive test to replace liver biopsy in renal transplant workup for HCV-positive
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I N T R O D U C T I O N
Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in renal transplant recipients [1] . Depending on geographical area, the prevalence of HCV among these patients ranges from 6 to 49% [2] [3] [4] [5] . HCV-infected patients who subsequently receive kidney transplantation have better survival compared with those who remain on dialysis [6] [7] [8] . However, those with pre-transplant biopsy-proven cirrhosis have poorer transplant outcomes when compared with those with lesser fibrosis [9] . Thus, it is generally recommended that HCV-positive transplant candidates undergo a liver biopsy [10, 11] . Although recent studies suggest that kidney transplant may be safe in end-stage renal disease (ESRD) patients with compensated HCV cirrhosis, advanced fibrosis (F3-F4) or cirrhosis (F4) is still regarded as a contraindication for renal transplantation alone by most centers.
Liver biopsy remains the gold standard for staging fibrosis despite the potential sampling errors of the procedure [12, 13] . Regarding ESRD patients, there is also reluctance by some physicians to perform biopsies on them due to the platelet function abnormalities of these patients and subsequent risk of significant bleeding [14] . As a result, there have been several efforts to find non-invasive markers to predict liver fibrosis in HCV-positive patients, including the aspartate aminotransferase to platelet ratio index (APRI). However, the majority of these are on non-uremic patients [15] [16] [17] [18] [19] [20] [21] [22] . The value and application of APRI has been less studied in those with concurrent ESRD. Assessing biochemical indices in this patient population could be potentially altered because aminotransferase activity is usually lower in dialysis patients compared with non-uremic patients [23] . In a recent study on ESRD, HCVpositive patients, the authors reported an area under curve (AUC) of 0.83 for APRI predicting significant fibrosis (F2-F4) and suggested that the index could be applied in this patient population to decrease the need of liver biopsy [18] . Notably, the use of APRI to predict F3-F4 was not addressed in the study. In patients being evaluated for renal transplant, these data are more clinically relevant because F3-F4 is usually a contraindication for renal transplant alone. So, the APRI, when validated fully in the ESRD population, may become useful in limiting the biopsies performed for those being evaluated for renal transplant [24] .
Currently at the University of California, Los Angeles (UCLA), we require that all HCV-positive patients complete a liver biopsy as a part of kidney transplant workup. As such, we have a large data repository on the biopsy findings of potential renal transplant candidates. To assess whether the number of biopsies could be efficiently decreased in this population by using non-invasive measures, including APRI, we analyzed HCV-positive patients referred to UCLA for renal transplantation workup from 2000 to 2012. So, although liver biopsies are routinely done as a part of a complete transplant workup, is this practice still completely necessary?
M AT E R I A L S A N D M E T H O D S

Study population
A total of 468 anti-HCV-positive patients were referred to UCLA medical center for kidney transplantation from January 2000 to August 2012. Our study population only included the 255 patients with liver biopsy data in our medical records. Patients who were not listed for renal transplant alone or were listed inactive prior to undergoing liver biopsy during transplant workup were excluded from our study (n = 213). Furthermore, out of 213 excluded patients, 154 of them (72%) did not complete the workup because of non-medical reasons. The study was approved by our institutional review board.
Methods
All information including demographic, laboratory, radiological and biopsy data was collected and reviewed from medical records. Normal values for laboratory tests were not adjusted for the change of normal values over time; however, we used the aspartate aminotransferase (AST) upper normal limit value to calculate the APRI index. Laboratory values and radiological data from the date closest to biopsy date were used. The AST to platelet ratio index (APRI) used was: [(AST/ upper limit of normal)/platelet count (10 9 /L)] × 100. For analysis of the predictive model of having any laboratory abnormality, those missing any laboratory values: alanine aminotransferase (ALT), AST, albumin, bilirubin, platelet and international normalized ratio (INR) were excluded (n = 39, 15%).
Histological analysis was categorized using the METAVIR scoring system. Fibrosis was scored from F0 to F4: F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = portal fibrosis with few septa, F3 = numerous septa without cirrhosis and F4 = cirrhosis. Radiological data were collected for patients who had ultrasound or abdominal computed tomography (CT) (n = 173, 68%). Radiological findings collected and categorized for analysis included the following: normal, suggestive of cirrhosis, coarsened liver, and the presence of ascites.
Statistical analysis
Patient laboratory characteristics were expressed as the median values with 25 and 75% quartiles reported. Categorical variables were compared using the chi-squared test. Means or medians of continuous variables were compared using either the t-test or the Mann-Whitney test, as appropriate. A P-value of ≤0.05 was considered statistically significant. The cutoff points for abnormal laboratory values were based on the receiver operating characteristics curves. APRI cutoffs were also based on previously established studies [18, 19] . The diagnostic accuracy of the predictive models was analyzed by calculating sensitivity, specificity, positive predictive value and negative predictive value. All analyses were performed using the STATA Statistical Software, Release 11 (StataCorp LP, College Station, TX, USA).
R E S U LT S
Patient characteristics
A total of 468 patients with a previous diagnosis of hepatitis C infection were evaluated at our institution for kidney transplantation from 2000 to 2012. Of these, 213 were listed inactive prior to receiving a liver biopsy and full transplant evaluation workup was not pursued. A total of 255 patients with hepatitis C seeking kidney transplantation were evaluated with a liver biopsy as part of their pre-transplant evaluation.
Of the 255 patients who underwent a liver biopsy, 45 (17.6%) were not considered further for kidney transplantation due to stage 3 or 4 fibrosis. One patient had stage 3 fibrosis and was not denied a transplant because of response to previous interferon therapy. There were 210 patients who underwent liver biopsy and were listed for kidney transplantation. Of these, 81 ultimately received kidney transplantation and 129 were listed and have yet to receive a transplant as of end of study follow-up (Figure 1) . Table 1 shows the overall baseline characteristics of the 255 patients with liver biopsy. The mean age of patients was 52.4 ± 9.3 years and they were predominantly male (76%). A fibrosis score of 0 (F0) was observed in 17.7% of patients, while 36.6% showed stage 1 fibrosis (F1), 27.6% had stage 2 (F2), 14.2% had stage 3 (F3) and 3.9% had stage 4 (F4).
Liver fibrosis associated variables To find factors that were correlated with fibrosis, we compared groups with METAVIR scores of F0-F1 to those with F3-F4, the cutoff for acceptance or rejection of potential kidney transplant. Table 2 shows the factors associated with advanced fibrosis (F3-F4) . In our univariate model, we found statistically significant differences between groups in terms of AST (P = 0.007), bilirubin (P ≤ 0.001), platelet count (P = 0.01) and APRI (P ≤ 0.001).
Predictive models for biopsy-proven F3-F4 Table 3 describes the performance characteristics of potential predictive models for F3-F4. The use of any one laboratory abnormality, again, did not show very high positive predictive values (22.6-72.7%). However, the use of any laboratory test to predict F3-F4 did show negative predictive values of >81%, including the APRI of <0.40, which had a negative predictive value of 86.7%. The use of a bilirubin level of >1.1 mg/dL to predict F3-F4 had specificity of 98.3 and positive predictive value of 72.7%, but again, had a very low sensitivity of 17.8%.
Imaging criteria to predict F3-F4 showed that a finding suggestive of cirrhosis had 100% specificity and positive predictive value. For this group, 14/104 (13%) of those having normal findings had F3-F4. Having other abnormal liver findings or cirrhosis on imaging was still associated with high specificities (92.0-97.8%) and moderately high positive predictive values (85.4-86.4%). Although slightly increased, the sensitivities observed were still low (31.4-42.9% ). 
O R I G I N A L A R T I C L E
L i v e r e v a l u a t i o n i n H C V + r e n a l t r a n s p l a n t c a n d i d a t e s APRI as a predictive model APRI levels were analyzed stratified by fibrosis level. Median APRI value for those with F0 was 0.35, F1 was 0.34, F2 was 0.41, F3 was 0.66 and F4 was 0.34. We further evaluated APRI as a predictive model of advanced fibrosis, using two cutoffs, <0.4 and >0.95 (Table 4) 
D I S C U S S I O N
Advanced fibrosis and cirrhosis (F3-F4) are usually contraindications for renal transplantation. In a previous study, Mathurin et al. [9] showed that 10-year kidney recipient survival was significantly lower in patients with pre-transplant biopsy-proven cirrhosis (33%) than those with lesser fibrosis (69%). Previous studies of HCV-positive patients undergoing renal transplant evaluation have reported up to 25% having bridging fibrosis or cirrhosis on biopsy [10, 11, 25, 26] . Our single center study shows a prevalence of 18.1% with F3-F4 ( Table 1 ). This represents a significant portion of this population that should be identified in order to avoid a potentially worse outcome following kidney transplantation.
Several laboratory values have previously been shown to be correlated with fibrosis, including AST levels, platelet count and the APRI index [18, 19, 22] . We wanted to examine correlation of factors with F3-F4, as this is the usual cutoff for acceptance or rejection of renal transplant candidacy. Our results are in line with findings of other studies, as it was shown that higher AST, lower platelet, higher bilirubin and higher APRI were correlated with F3-F4 ( Table 2) . Although statistically different, these results may not be as clinically relevant because most of the median laboratory values for those with F3-F4 were still in normal limits.
We then evaluated these factors as potential simple markers for predicting advanced fibrosis ( Table 3) . As a potential predictor of fibrosis, there was no test that showed both high sensitivity and specificity. Likewise, none possess both high positive predictive value and negative predictive value. All negative predictive values increased dramatically when markers were used to predict F3-F4. The absence of any laboratory abnormality was associated with 96% negative predictive value, showing that a combination of normal laboratory values could potentially be of use in excluding advanced fibrosis. Of note, using bilirubin >1.1 mg/dL as a cutoff was associated with 98.3% specificity and 72.7 positive predictive value for F3-F4. However, out of the 218 patients with bilirubin data, only 11 (5%) exhibited levels higher than 1.1 mg/ dL. Of the 11, 9 had at least F3 on biopsy.
Radiological studies have shown that ultrasound is useful for detecting cirrhosis, but is not an accurate predictor of early liver fibrosis [27, 28] . Our results show a similar trend. It is not surprising that having radiological reports mentioning a suspicion for cirrhosis (n = 11, 6%) showed 100% specificity and positive predictive value for predicting F2 or greater. However, it showed low sensitivities (F3-F4: 31.4%), like the other radiological parameters we tested (Table 3) . Our results indicate that imaging including ultrasound can be useful when positive for features that would suggest cirrhosis. However, caution is necessary due to the low sensitivity of the test to predict fibrosis and a significant number of those with normal appearing ultrasounds or abdominal CTs can still have significant fibrosis or cirrhosis when biopsy is performed (13% for F3-F4) . A few studies have proposed that the APRI is a useful test to predict significant liver fibrosis in HCV + ESRD patients and that its use could potentially decrease the need for liver biopsy in this population [18, 19] . When dual cutoffs of <0.40 and >0.95 were used, Schiavon et al. reported a negative predictive value of 93% to predict F0-F1 and a positive predictive value of 66% to predict F2-F4. They concluded that 52% of liver biopsies could have been correctly avoided using this system. A more recent study by Liu et al. reported similar findings about the efficacy and reliability of the APRI. In our study, we looked at APRI extensively and found that the specificity and positive predictive values showed comparable results (Table 4) . However, our sensitivities and negative predictive values are slightly lower. When APRI is used to predict F3-F4, which is more useful for transplant evaluation purposes, 50% would have correctly avoided having a biopsy. However, caution needs to be applied because 15/45 (33%) of patients with F3-F4 would not be indicated for biopsy and could go on to receive a kidney transplant when they would be at greater risk for poor outcomes. At the same time, 14/175 (8%) of those with F0-F2 would be subjected to unnecessary risks of biopsy.
There was a general upward trend in APRI value through increasing fibrosis scores of 1-3 with an unexpected drop in those with stage 4 fibrosis. A decreased value of 0.34 could just be a result of a small number of those with stage 4 fibrosis (10/ 255, 3.9%). However, it could also indicate a plausible result for those with very late stage liver disease, in which the destroyed liver would release less liver enzymes.
Non-invasive measures other than APRI have also been proposed as a way to assess hepatic fibrosis. Transient elastography (TE, Fibroscan), which is used to assess liver stiffness, has been brought up as a test that could be used to predict the severity of fibrosis [29] . Munoz et al. [30] showed that a higher fibrosis score was correlated with a higher Fibroscan score (expressed in kilopascals); however, the study was limited by sample size. A more recent study looked at TE use on hemodialysis patients and showed that for predicating advanced fibrosis (contraindication for transplant), the AUC of TE was 0.98 compared with 0.93 for APRI [31] . While APRI is widely available and limited in cost, the use of TE is currently not approved for use in the USA. As a result, our study lacks the TE data to effectively analyze this modality.
Our study comes with some limitations. First, this is a retrospective analysis that is subject to potential selection and reporting bias. Second, our study is based on the assumption that liver biopsy is the gold standard for predicting fibrosis. This, however, would be common to any study whose purpose is to correlate non-invasive markers to liver fibrosis. Third, not all 100% of the labs in the analysis used were necessarily done at UCLA (although the vast majority were, some were possibly done at the referring center). Lastly, we have a low prevalence of patients with biopsy-proven stage 4 cirrhosis (3.9%) and those with bilirubin >1.1 g/dL (5%), making it difficult to generalize these findings to other patient populations.
In conclusion, our data suggest that there may not currently be a simple and sufficiently accurate non-invasive test to adequately replace liver biopsy in the setting of HCV-positive patients being evaluated for renal transplantation. While the use of APRI could prevent 50% of patients to undergo a liver biopsy, the very same APRI could miss 33% of those with advanced fibrosis, and allow transplantations known to be associated with poor prognosis to be performed. We feel that because of this, the risks outweigh the benefits and caution needs to be used when applying the APRI as a way to substitute liver biopsy. 
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